Co9.0

Choline

Choline

An essential nutrient that supports brain function, liver health, and cell membrane integrity - a precursor to acetylcholine.

mentalimmunitybrain healthacetylcholinenootropicliver health
Last reviewed: January 1, 2025
9.0/10
40+ studies
Evidence
high
Safety
250-500mg daily (varies by form)
Dose
2-8 weeks
Time to Effect
Alpha-GPC or CDP-Choline (Citicoline)
Best Form

Choline is an essential nutrient similar to B vitamins, required for neurotransmitter synthesis (acetylcholine), cell membrane structure (phosphatidylcholine), and liver function (lipid transport). Most people don't get enough choline from diet alone. It's particularly important for cognitive function, as acetylcholine is crucial for memory and learning. Different forms (Alpha-GPC, CDP-Choline, choline bitartrate) have varying effects and bioavailability.

Mechanisms of Action

🧠
Acetylcholine Synthesis

Precursor to the memory and learning neurotransmitter

🔵
Cell Membrane Structure

Component of phospholipids that form cell membranes

🔄
Methylation Support

Donates methyl groups via betaine pathway

Recommended Dose

250-500mg daily (varies by form)

100mg3500mg

Loading: Not required; choose dose based on dietary intake

Optimal Timing

  • Morning or with meals
  • Alpha-GPC before cognitive tasks

Take with food

Best Form

Alpha-GPC or CDP-Choline (Citicoline)

Alternatives: Choline Bitartrate, Phosphatidylcholine, Lecithin

Alpha-GPC: 40% choline, best for cognition. CDP-Choline: Also provides cytidine for brain health. Bitartrate: Cheapest, good for basic needs. Lecithin: Food-based, lower choline content.

Duration

Minimum: 2 weeks

Optimal: 8 weeks

Cycling: Not required

Note: Different forms have different optimal uses: Alpha-GPC for cognitive enhancement, CDP-Choline for neuroprotection, choline bitartrate for basic choline needs.

Personalized Dosage Calculator

Get a dosage recommendation tailored to your body weight, age, goals, and health profile.

Set up your health profile for personalized recommendations

🧠
Improved Memory

Better recall and working memory

2-4 weeks
65% of users notice thispositive
🔴
Liver Health Support

Healthy fat metabolism and liver function

4-8 weeks
80% of users notice thispositive
✨
Mental Clarity

Clearer thinking and focus

1-2 weeks
60% of users notice thispositive
🐟
Fishy Body Odor

High doses may cause trimethylaminuria-like odor

With high doses
15% of users notice thistrade-off
High SafetyMax safe dose: 450 mg/day in pregnancy; 550 mg/day in lactation
🟢
Pregnant/nursing

Important nutrient; 450-550mg/day recommended during pregnancy

🟡
Elderly

May support cognitive function; consider Alpha-GPC or CDP-Choline

Who Should NOT Take This

  • Trimethylaminuria (fish odor syndrome)

Drug Interactions

Acetylcholinesterase inhibitorsmild

May enhance cholinergic effects

Anticholinergic medicationsmild

May reduce effectiveness of either

Possible Side Effects

Fishy body odoruncommon

Tip: Reduce dose; affects some individuals more

GI upsetuncommon

Tip: Take with food

Headacherare

Tip: May indicate cholinergic excess; reduce dose

Warnings

  • Very high doses may cause fishy body odor
  • Choose form based on specific goals

Top studies from 40+ peer-reviewed papers

meta-analysisn=33009
DOI

Yang Q et al. • European journal of clinical investigation (2023)

“Higher levels of circulating choline were associated with a higher risk of CVD and all-cause mortality.”
Key Findings:
  • Random-effects model results showed that highest versus lowest quantile of circulating choline concentrations were associated with the risk of CVD (RR = 1.29, 95% CI: 1.04-1.61) and all-cause mortality (RR = 1.62, 95% CI: 1.12-2.36).
  • We also observed the risk of CVD were increased 13% (5%-22%) with per SD increment.
  • Furthermore, highest versus lowest quantile of circulating betaine concentrations were not associated with the risk of CVD (RR = 1.07, 95% CI: 0.92-1.24) and all-cause mortality (RR = 1.39, 95% CI: 0.96-2.01).
  • However, the risk of CVD was increased 14% (5%-23%) with per SD increment.
rctn=198
DOI

Ost P et al. • The Lancet. Oncology (2025)

“To our knowledge, this is the first randomised trial for metachronous PET-detected nodal recurrences comparing two local treatment approaches (MDT and ENRT) in combination with 6 months of androgen deprivation therapy.”
Key Findings:
  • To our knowledge, this is the first randomised trial for metachronous PET-detected nodal recurrences comparing two local treatment approaches (MDT and ENRT) in combination with 6 months of androgen deprivation therapy.
  • By showing an improved metastasis-free survival with ENRT, this trial establishes ENRT as a potential standard treatment approach, awaiting a phase 3 trial confirming these results.
  • Further research warranted to confirm findings
meta-analysisn=482778
DOI

Sharifi-Zahabi E et al. • Nutrition research (New York, N.Y.) (2024)

“All rights reserved.”
Key Findings:
  • This study showed that each 100 mg/day increment in choline consumption was significantly associated with a 6% and 11% higher risk of all-cause and cardiovascular disease mortality respectively.
  • In addition, a significant positive relationship between betaine intake and stroke mortality at doses of 50 to 250 mg/day was observed.
  • Due to the small number of the included studies and heterogeneity among them more well-designed prospective observational studies considering potential confounding variables are required.Copyright © 2024 Elsevier Inc.
  • All rights reserved.
meta-analysis
DOI

Thomson AR et al. • Neuroscience and biobehavioral reviews (2024)

“All rights reserved.”
Key Findings:
  • Data were extracted and grouped by metabolite, brain region and several other factors before calculation of standardised effect sizes.
  • Further analysis found these alterations are most pronounced in autistic children and in limbic brain regions relevant to autism phenotypes.
  • Additionally, we show how study outcome varies due to demographic and methodological factors , emphasising the importance of conforming with standardised consensus study designs and transparent reporting.Copyright © 2024 The Authors.
  • Published by Elsevier Ltd..
meta-analysisn=1326
DOI

Sagaro GG et al. • Journal of Alzheimer's disease : JAD (2023)

“α-GPC alone or in combination with donepezil improved cognition, behavior, and functional outcomes among patients with neurological conditions associated with cerebrovascular injury.”
Key Findings:
  • We found significant effects of α-GPC in combination with donepezil on cognition [4 RCTs, mean difference (MD):1.72, 95% confidence interval (CI): 0.20 to 3.25], functional outcomes [3 RCTs, MD:0.79, 95% CI: 0.34 to 1.23], and behavioral outcomes [4 RCTs; MD: -7.61, 95% CI: -10.31 to -4.91].
  • We also observed that patients who received α-GPC had significantly better cognition than those who received either placebo or other medications [MD: 3.50, 95% CI: 0.36 to 6.63].
  • α-GPC alone or in combination with donepezil improved cognition, behavior, and functional outcomes among patients with neurological conditions associated with cerebrovascular injury.
39
Total Studies
9.1/10
Avg Quality
10-482,778
Sample Size Range
2005-2025
Research Span

Study Type Distribution

Meta-Analysis
21
RCT
13
Systematic Review
5

This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.